Constructed in under two years on a 5.2-hectare plot in the Pirallahi Industrial Park, the production complex was commissioned on October 5, 2026. The industrial investment directly supports Azerbaijan's sovereign healthcare goals by reducing reliance on imported essential medicines.
The facility operates under a joint venture structure where GEN İlaç holds a 66% controlling stake, the Azerbaijan Business Development Fund (under the Ministry of Economy) holds 29%, and SIA Pharmaceuticals holds 5%.
Targeted Output: 50 Formulations by 2027, 500+ Over Five Years
Key operational parameters and milestones of the industrial site include:
Production Volumes & Workforce: Designed for an annual capacity of 60 million commercial packs and 2.5 billion solid-dose units (tablets and capsules), creating 178 direct permanent jobs.
Therapeutic Focus: Prioritizes localized manufacturing across cardiology, neurology, urology, diabetology, gastroenterology, antibiotics, and analgesics.
Phased Commercial Timeline: The site aims to operationalize 50 formulations by 2027, scaling to localize over 500 pharmaceutical products within five years.
Regional Export Gateway: Beyond fulfilling Azerbaijani domestic market requirements, the plant will export finished pharmaceuticals across Central Asia and the Caucasus, including Uzbekistan, Kazakhstan, and Georgia.
Academic Partnerships: Houses formal training hubs for Karabakh University and Azerbaijan Medical University to develop domestic pharmaceutical talent.
Executive Commentary from Abidin Gülmüş
Abidin Gülmüş, Chairman of the Board at GEN:
GEN continues to invest, manufacture for healthcare, and maintain sustainable growth despite broader regional challenges. This manufacturing complex in Azerbaijan represents a tangible reflection of the bilateral economic cooperation between Turkey and Azerbaijan, serving as an important milestone in GEN’s international expansion. Our priority is to locally produce critical medicines required by the Azerbaijani healthcare system, while eventually extending this manufacturing reach to neighboring regional markets to improve patient access to essential treatments.
